Tharimmune Inc., a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology, has announced an option agreement for an exclusive license with Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2.   “HER2 remains an important tumor target where the need for novel treatments against this receptor will contin...